Edel del
Barco Morillo
Profesor Asociado CC. Salud
![Foto de Edel del](/img/uploaded/8A2B27B9F7D886278B8B7622032A2C54.jpg)
![Foto de Hospital Universitario Puerta de Hierro](/img/noimage_org.png)
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (16)
2024
-
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663
2023
-
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
ERJ Open Research, Vol. 9, Núm. 6
-
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128
2022
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Lung cancer patients with COVID-19 in Spain: GRAVID study
Lung Cancer, Vol. 157, pp. 109-115
-
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
BMC Cancer, Vol. 21, Núm. 1
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
2013
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121